Inimmune Inc.
October 15, 2024
Hunt Room
Oncology
Inimmune designs and develops novel immunotherapeutic compounds and delivery systems that
target relevant pathways of the innate immune system to drive disease-modifying responses in areas of
high unmet medical need. Our lead clinical programs include a TLR4 agonist, INI-2004, for seasonal allergic
rhinitis and a TLR7/8 agonist, INI-4001, for cancer delivered in proprietary liposomal formulations.
In addition, Inimmune develops novel vaccine adjuvants and has entered into a worldwide commercialization & distribution agreement with SPI for selected vaccine adjuvants from the Inimmune portfolio.